Symptoms, ultrasound imaging and biochemical markers alone or in combination for the diagnosis of ovarian cancer in women with symptoms suspicious of ovarian cancer
Referencias
Additional references
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin no 83. Management of adnexal masses. Obstetrics and Gynecology 2007;110(1):201‐14.
Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case–control study. Journal of the National Cancer Institute 2010;102(1):26‐38.
Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG: An International Journal of Obstetrics and Gynaecology 2005;112(7):857‐65.
Cho KR, Shih I. Ovarian cancer. Annual Review of Pathology Mechanisms of Disease 2009;4:287–313.
Chu H, Cole SR. Bivariate meta‐analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. Journal of Clinical Epidemiology 2006;59(12):1331‐2.
Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. Available from: http://srdta.cochrane.org/handbook‐dta‐reviews (accessed October 2015)2013.
Cancer Research UK. Ovarian cancer mortality statistics. http://www.cancerresearchuk.org/health‐professional/cancer‐statistics/statistics‐by‐cancer‐type/ovarian‐cancer/mortality (accessed October 2015).
Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. Journal of Clinical Epidemiology 2005;58(9):882‐93.
Duklewski K, Aronson A. Ovarian cysts. eMedicine. Stearns DA, et al (editors). 18 June 2007. Medscape 28 July 2009 http://www.mdguidelines.com/ovarian‐cyst‐benign(accessed October 2015).
Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. Journal of Clinical Pathology 2013;66(4):273‐81.
Fitch M, Deane K, Howell D, Gray RE. Women's experiences with ovarian cancer: reflections on being diagnosed. Canadian Oncology Nursing Journal (Revue Canadienne de Nursing Oncologique) 2002;12(3):152‐68.
Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstetrics and Gynecology 2009;113(2 Pt 1):384‐94.
Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007;109(2):221‐7.
Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. American Journal of Obstetrics and Gynecology 2011;205(4):358 .e1‐6.
Jacobs I, Bast RC. The CA 125 tumour‐associated antigen: a review of the literature. Human Reproduction 1989;4(1):1‐12.
Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. British Journal of Obstetrics and Gynaecology 1990;97(10):922‐9.
Kaijser J, Sayasneh A, Van Hoorde K, Ghaem‐Maghami S, Bourne T, Timmerman D, et al. Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta‐analysis. Human Reproduction Update 2014;20(3):449‐62.
Koonings PP, Campbell K, Mishell DR, Grimes DA. Relative frequency of primary ovarian neoplasms: a 10‐year review. Obstetrics and Gynecology 1989;74(6):921‐6.
Li F, Tie R, Chang K, Wang F, Deng S, Lu W, et al. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta‐analysis. BMC Cancer 2012;12:258.
Lim AW, Mesher D, Gentry‐Maharaj A, Balogun N, Jacobs I, Menon U, et al. Predictive value of symptoms for ovarian cancer: comparison of symptoms reported by questionnaire, interview, and general practitioner notes. Journal of the National Cancer Institute 2012;104(2):114‐24.
Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. Journal of Clinical Pathology 2005;58(3):308‐12.
Myers ER, Bastian LA, Havrilesky LJ, Kulasingam SL, Terplan MS, Cline KE, et al. Management of adnexal mass. AHRQ Report 2006;130:1‐145.
National Institute for Health and Care Excellence. CG 122: Ovarian cancer: the recognition and initial management of ovarian cancer. https://www.nice.org.uk/guidance/cg122/chapter/guidance (accessed October 2015)2011.
Posadas EM, Davidson B, Kohn EC. Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Current Opinion in Oncology 2004;16(5):478‐84.
Rai N, Nevin J, Downey G, Abedin P, Balogun M, Kehoe S, et al. Outcomes following implementation of symptom triggered diagnostic testing for ovarian cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology 2015;187:64‐9.
Royal College of Obstetricians and Gynaecologists. Guideline 34: Ovarian cysts in postmenopausal women. https://www.rcog.org.uk/globalassets/documents/guidelines/gtg34ovariancysts.pdf (accessed October 2005)2010.
Royal College of Obstetricians and Gynaecologists. Guideline no 62: Management of suspected ovarian masses in premenopausal women. https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_62.pdf (accessed October 2015)2011.
Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology 2005;58(10):982‐90.
Riley RD, Ahmed I, Ensor J, Takwoingi Y, Kirkham A, Morris RK, et al. Meta‐analysis of test accuracy studies: an exploratory method for investigating the impact of missing thresholds. Systematic Reviews 2015;4(1):12.
Rutter CM, Gatsonis CA. A hierarchical regression approach to meta‐analysis of diagnostic test accuracy evaluations. Statistics in Medicine 2001;20(19):2865‐84.
Sarojini S, Tamir A, Lim H, Li S, Zhang S, Goy A, et al. Early detection biomarkers for ovarian cancer. Journal of Oncology 2012;2012:709049.
Copyright, SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA. SAS software version 9.2. Copyright, SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA, 2009.
Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. American Journal of Surgical Pathology 2003;27(7):985‐93.
Shepherd JE. Current strategies for prevention, detection, and treatment of ovarian cancer. Journal of the American Pharmaceutical Association 2000;40(3):392‐401.
Shih I, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. American Journal of Pathology 2004;164:1511–8.
StataCorp LP. College Station, TX. Stata 14. StataCorp LP. College Station, TX, 2015.
Takwoingi Y, Leeflang MM, Deeks JJ. Empirical evidence of the importance of comparative studies of diagnostic test accuracy. Annals of Internal Medicine 2013;158(7):544‐54.
Van Calster B, Timmerman D, Valentin L, McIndoe A, Ghaem‐Maghami S, Testa AC, et al. Triaging women with ovarian masses for surgery: observational diagnostic study to compare RCOG guidelines with an International Ovarian Tumour Analysis (IOTA) group protocol. BJOG: An International Journal of Obstetrics and Gynaecology 2012;119(6):662‐71.
Van Calster B, Van Hoorde K, Valentin L, Testa AC, Fischerova D, Van Holsbeke C, et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ 2014;349:g5920.
Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer 2011;11(10):719‐25.
Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clinical Cancer Research 2008;14(4):1065‐72.
Wiegand KC, Shah SP, Al‐Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis‐associated ovarian carcinomas. New England Journal of Medicine 2010;363(16):1532‐43.
Wolff R, Whiting P, Mallett S, Riley R, Westwood M, Kleijnen J, et al. Prediction study risk of bias assessment tool (PROBAST). Evidence‐Informed Public Health: Opportunities and Challenges. Abstracts of the 22nd Cochrane Colloquium; 2014 Sep 21‐26. John Wiley & Sons, Ltd, 2014:141.
